2C-T-17

2C-T-17, also known as 4-sec-butylthio-2,5-dimethoxyphenethylamine or as Nimitz, is a psychedelic drug of the phenethylamine and 2C families.^[1] It is taken orally.^[1]

2C-T-17

Clinical data
Other names	4-sec-Butylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-sec-butylthiophenethylamine; NIMITZ; Nimitz
Routes of administration	Oral[1]
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None
Pharmacokinetic data
Duration of action	10–15 hours[1]
Identifiers
IUPAC name 2-(4-butan-2-ylsulfanyl-2,5-dimethoxyphenyl)ethanamine
CAS Number	207740-32-7 Y[chemspider]
PubChem CID	44349798
ChemSpider	21106230 Y
UNII	NLC3VH4KZM
ChEMBL	ChEMBL127284 Y
CompTox Dashboard (EPA)	DTXSID20658365
Chemical and physical data
Formula	C14H23NO2S
Molar mass	269.40 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(CC)Sc1cc(OC)c(cc1OC)CCN
InChI InChI=1S/C14H23NO2S/c1-5-10(2)18-14-9-12(16-3)11(6-7-15)8-13(14)17-4/h8-10H,5-7,15H2,1-4H3 Y Key:KSZHVRPGICAZOA-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991.^[2] Shortly after this, Shulgin described 2C-T-17 in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).^[1]

Use and effects

According to Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved), 2C-T-17's dose range is 60 to 100 mg and its duration is 10 to 15 hours.^[1] Its onset is 1 hour and peak effects occurred after 3 hours.^[1] 2C-T-17 has been described as a "truly heavy psychedelic" but as producing no psychedelic visuals and very little in the way of perceptual changes.^[1] User reports described it as having pronounced psychoactive effects but had difficulty describing exactly what those effects were.^[1]

Toxicity

The toxicity of 2C-T-17 is not well-documented.^{[citation needed]} It is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.^{[citation needed]}

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

The mechanism of action that produces 2C-T-17's hallucinogenic effects has not been specifically established, however it is most likely to result from action as a serotonin 5-HT_2A receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.^{[citation needed]}

Chemistry

2C-T-17 is the 2 carbon homologue of Aleph-17, which has never been synthesized.^[1] The full chemical name is 2-[4-(2-butyl thio)-2,5-dimethoxy phenyl]ethanamine.^[1] The drug has structural properties similar to drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-8.^[1]

History

2C-T-17 was first described in the scientific literature by Alexander Shulgin and colleagues in a journal article in 1991.^[2] Shortly thereafter, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).^[1]

Society and culture

Legal status

Canada

As of October 31, 2016, 2C-T-17 is a controlled substance (Schedule III) in Canada.^[3]

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.^[4]

United States

2C-T-17 is not illegal, but possession and sales of 2C-T-17 could be prosecuted under the Federal Analog Act in the United States because of its structural similarities to 2C-T-7.

See also

• 2C (psychedelics)
• ASR-3001 (5-MeO-iPALT)
• MiPT